Theta-Burst Versus 10-Hz TMS: What a Shorter Session Does—and Does Not—Mean

A shorter TMS session can make treatment easier to fit around work, transport, and caregiving. But the phrase shorter treatment can describe several very different changes: fewer minutes of stimulation, fewer visits, or multiple sessions compressed into fewer days. Understanding which change is being offered matters because evidence for one does not automatically support the others. Intermittent theta-burst stimulation, or iTBS, is a useful example of that distinction.

Two ways of organizing magnetic pulses

Conventional 10-Hz repetitive TMS and iTBS use different pulse patterns. Both can be delivered to a prefrontal target in depression treatment, but the timing of stimulation differs. A description of the pulse pattern alone does not identify the entire protocol. Intensity, target, number of pulses, visit frequency, and patient population also matter. A clinic should explain the complete treatment being proposed rather than treating theta burst as a sufficient specification.

The Blumberger et al., THREE-D randomized noninferiority trial, 2018 compared approximately three-minute iTBS stimulation with a substantially longer 10-Hz session in adults with depression. The practical attraction was reducing session duration while retaining effectiveness within the tested framework. That is a meaningful access question, especially when repeated visits are required. It does not mean that the assessment, positioning, communication, and other parts of every appointment can all be completed in three minutes.

What noninferiority tested

THREE-D randomized 414 participants and used a noninferiority design. The question was whether iTBS performed acceptably close to the established active comparator within a prespecified margin, using a defined depression outcome. It was not a demonstration that every individual would have the same experience or outcome with either protocol. Group-level comparability does not eliminate differences in discomfort, preferences, scheduling, or clinical suitability.

Because both groups received active treatment, this study should not be described as a sham-controlled proof that each intervention exceeds placebo under those same conditions. Its central contribution is comparative effectiveness. That distinction does not weaken the relevance of the trial; it makes the question it answers clearer. Ask whether a clinic's explanation preserves that distinction when it cites noninferiority as evidence for a shorter option.

Session duration and course duration are separate

Reducing minutes of stimulation may lower the time burden of each visit without reducing the number of visits. A patient still needs to account for travel, check-in, positioning, and progress review. A shorter protocol can therefore offer a real benefit while remaining difficult to access for someone who lives far from a clinic. Ask for the full proposed schedule before estimating work absence or transport costs.

By contrast, accelerated treatment delivers multiple sessions within a day or otherwise compresses the course. The Cole et al., Stanford Neuromodulation Therapy randomized trial, 2022 evaluated a specific bundled approach involving individualized targeting and high-dose accelerated iTBS. Its evidence cannot be inferred merely from THREE-D. A service offering a different accelerated schedule should identify the evidence for that schedule rather than claiming that all theta-burst approaches are interchangeable.

Tolerability still deserves discussion

A shorter session is not necessarily a sensation-free session. Patients may experience scalp discomfort and need to communicate with staff about positioning and tolerability. Ask how the team responds if the proposed pattern is difficult to tolerate and how any change would affect the treatment plan. Do not interpret discomfort as proof of effectiveness or a reason to increase stimulation independently.

The TMS course decision guide explains how safety screening, practical planning, and reassessment fit together. A clinician should discuss the person's medical history and the relevant device instructions regardless of which pulse pattern is selected. The convenience of a shorter session should be weighed alongside appropriateness, evidence, and the ability to attend consistently, rather than presented as the only meaningful distinction.

Questions that make a comparison useful

Ask which protocol is proposed, which study most closely matches it, and whether the goal is to shorten each visit or compress the whole course. Clarify what stays the same and what changes. If outcomes are quoted, request the definition, time point, and population. A percentage from one protocol should not be attached to another merely because both use a TMS coil and the term theta burst.

For the compressed-course question, read our accelerated-schedule appraisal. For a broader evidence framework, see the protocol evidence guide. The durable lesson from THREE-D is not that treatment time no longer matters or that all short protocols work alike. It is that a carefully tested change in session structure can be evaluated directly—and that later changes deserve the same discipline.

Medical disclaimer: This article provides general education, not diagnosis, individualized treatment advice, or emergency care. Evidence and regulatory statements refer to the dated sources cited, not an exhaustive verification of all changes through October 30, 2026.

Sources

1. Blumberger et al., THREE-D randomized noninferiority trial, 2018
2. Cole et al., Stanford Neuromodulation Therapy randomized trial, 2022